Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Hutton

Showing results (231-240 of 368) with videos related to

Pageof 37
Sort By:
American Journal of Clinical Pathology|April 1, 1982
Evaluation of methods of detecting terminal deoxynucleotidyl transferase in human hematologic malignancies. Comparison of immunofluorescence and enzymatic assaysM L Cibull, M S Coleman, O Nelson, et al.
Multiple Sclerosis and Related Disorders|September 29, 2024
Factors associated with the initiation of high-efficacy disease-modifying agents over moderate-efficacy disease-modifying agents in multiple sclerosisJieni Li, George J Hutton, Tyler J Varisco, et al.
The Bone & Joint Journal|June 2, 2017
Magnetically controlled growing rods in the treatment of early-onset scoliosis: a note of cautionP R P Rushton, I Siddique, R Crawford, et al.
Preventive Medicine|November 18, 2024
Comparative effectiveness of high-efficacy and moderate efficacy disease-modifying agents in reducing the annualized relapse rates among multiple sclerosis patients in the United StatesJieni Li, George J Hutton, Tyler J Varisco, et al.
Frontiers in Neurology|November 1, 2021
Cerebral Large Vessel Occlusion Caused by Fat Embolism-A Case Series and Review of the LiteratureSuyi Ooi, Subahari Raviskanthan, Bruce C V Campbell, et al.
Patient Preference and Adherence|November 12, 2020
Comparative Adherence Trajectories of Oral Fingolimod and Injectable Disease Modifying Agents in Multiple SclerosisJagadeswara R Earla, George J Hutton, J Douglas Thornton, et al.
The Journal of Clinical Investigation|August 1, 1981
Biochemical and functional abnormalities in lymphocytes from an adenosine deaminase-deficient patient during enzyme replacement therapyJ J Hutton, D A Wiginton, M S Coleman, et al.
Molecular Endocrinology (Baltimore, Md.)|April 1, 1989
Isolation and sequence analysis of cDNA for rat carboxypeptidase E [EC 3.4.17.10], a neuropeptide processing enzymeL D Fricker, J P Adelman, J Douglass, et al.
Pharmacotherapy|February 28, 2021
Comparative treatment effectiveness of oral fingolimod and conventional injectable disease-modifying agents in multiple sclerosisJagadeswara R Earla, George J Hutton, Douglas J Thornton, et al.
Exploratory Research in Clinical and Social Pharmacy|April 28, 2022
Factors associated with oral fingolimod use over injectable disease- modifying agent use in multiple sclerosisJagadeswara Rao Earla, George J Hutton, J Douglas Thornton, et al.
Pageof 37

Showing results (231-240 of 368) with videos related to

Sort By:
Pageof 37
American Journal of Clinical Pathology|April 1, 1982
Evaluation of methods of detecting terminal deoxynucleotidyl transferase in human hematologic malignancies. Comparison of immunofluorescence and enzymatic assaysM L Cibull, M S Coleman, O Nelson, et al.
Multiple Sclerosis and Related Disorders|September 29, 2024
Factors associated with the initiation of high-efficacy disease-modifying agents over moderate-efficacy disease-modifying agents in multiple sclerosisJieni Li, George J Hutton, Tyler J Varisco, et al.
The Bone & Joint Journal|June 2, 2017
Magnetically controlled growing rods in the treatment of early-onset scoliosis: a note of cautionP R P Rushton, I Siddique, R Crawford, et al.
Preventive Medicine|November 18, 2024
Comparative effectiveness of high-efficacy and moderate efficacy disease-modifying agents in reducing the annualized relapse rates among multiple sclerosis patients in the United StatesJieni Li, George J Hutton, Tyler J Varisco, et al.
Frontiers in Neurology|November 1, 2021
Cerebral Large Vessel Occlusion Caused by Fat Embolism-A Case Series and Review of the LiteratureSuyi Ooi, Subahari Raviskanthan, Bruce C V Campbell, et al.
Patient Preference and Adherence|November 12, 2020
Comparative Adherence Trajectories of Oral Fingolimod and Injectable Disease Modifying Agents in Multiple SclerosisJagadeswara R Earla, George J Hutton, J Douglas Thornton, et al.
The Journal of Clinical Investigation|August 1, 1981
Biochemical and functional abnormalities in lymphocytes from an adenosine deaminase-deficient patient during enzyme replacement therapyJ J Hutton, D A Wiginton, M S Coleman, et al.
Molecular Endocrinology (Baltimore, Md.)|April 1, 1989
Isolation and sequence analysis of cDNA for rat carboxypeptidase E [EC 3.4.17.10], a neuropeptide processing enzymeL D Fricker, J P Adelman, J Douglass, et al.
Pharmacotherapy|February 28, 2021
Comparative treatment effectiveness of oral fingolimod and conventional injectable disease-modifying agents in multiple sclerosisJagadeswara R Earla, George J Hutton, Douglas J Thornton, et al.
Exploratory Research in Clinical and Social Pharmacy|April 28, 2022
Factors associated with oral fingolimod use over injectable disease- modifying agent use in multiple sclerosisJagadeswara Rao Earla, George J Hutton, J Douglas Thornton, et al.
Pageof 37